" class="no-js "lang="en-US"> Leucadia Therapeutics - Medtech Alert
Sunday, September 14, 2025
Leucadia Therapeutics | Pharmtech Focus

Leucadia Therapeutics

About Leucadia Therapeutics

Leucadia Therapeutics

Leucadia Therapeutics is a pre-clinical-stage company focused on diagnosing, treating and curing Alzheimer’s disease. The company’s proprietary Arethusta® medical device is designed to restore the flow of CSF through the cribriform plate to flush toxins away from the part of the brain where Alzheimer’s disease first appears. The Arethusta implantation is easily reversible.

Leaucadia Therapeutics is taking a different approach to Alzheimer’s disease, which afflicts 44 million people and nearly one in 10 people over 70. Over the past three decades, more than $30 billion has been invested in 2,300 clinical trials for medicines to treat the disease.  None were able to slow or halt its relentless progression. Studies suggest Leucadia’s implantable device will prevent Alzheimer’s disease from developing, and may even reverse it in people who already have it.

Related Story

Prominent Neurosurgeon Joins Leucadia Therapeutics as Company's Founding Global Chief Medical Officer

August 23 2022

Leucadia Therapeutics, a company working to cure Alzheimer’s disease, has hired a global chief medical […]